Get started
Author

Anna Malovannaya

Observed name: A. Malovannaya
ORCID: 0000-0003-2953-6485
Observed ORCID: 0000-0003-2953-6485
OpenAlex ID: A5083790470
Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer
2025 · Y. Li, P. Yadollahi, et al. · Journal of Translational Medicine · 10
PDF
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor
2026 · Warren Fiskus, Christopher P. Mill, et al. · Blood · 4
Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
2024 · Jonathan T. Lei, Lacey E. Dobrolecki, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer
2025 · Matthew V. Holt, Yongchao Dou, et al. · Cell Reports Medicine · 2
EGR3 deletion attenuates developmental and epileptic encephalopathy in Kcna1 -null mice
2026 · Arindam Ghosh Mazumder, Saifina Karedia, et al. · Brain · 1
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
2026 · Chandra Sekhar Amara, Danthasinghe Waduge Badrajee Piyarathna, et al. · Cancer Letters
PDF
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML
2026 · Christine E. Birdwell, Warren Fiskus, et al. · Leukemia
PDF
Repeated Mild Head Injury Establishes a Senescent Cranial Bone Marrow Niche that Impairs Brain Metabolism
2026 · Patrick J. Devlin, Romeesa Khan, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high‐risk MECOM‐rearranged AML
2026 · Warren Fiskus, Christopher P. Mill, et al. · HemaSphere
PDF
Abstract PS4-02: Patient-derived Xenografts (PDX) Allow Deconvolution of Combination Chemotherapy Response
2025 · Jonathan Lei, Lacey E. Dobrolecki, et al. · Clinical Cancer Research
Abstract 739: Patient-derived xenografts allow deconvolution and prediction of chemotherapy responses
2025 · Jonathan T. Lei, Lacey E. Dobrolecki, et al. · Cancer Research
Abstract 5011: Targeting kinome reprogramming in ESR1 fusion-driven breast cancer
2023 · Xuxu Gou, Beom-Jun Kim, et al. · Cancer Research
Abstract P6-11-10: Investigating the role of mitochondrial protein translation in the metabolic adaptation of chemoresistant triple negative breast cancer
2023 · Mariah J. Berner, Lily Baek, et al. · Cancer Research
BATF2 Promotes HSC Myeloid Differentiation Via Amplification of the Pro-Inflammatory Response during Chronic Infection
2022 · Duy Le, Marcus A. Florez, et al. · Blood
Abstract 3922: Proteomic profiling of muscle invasive bladder cancer
2022 · Matthew V. Holt, Meggie N. Young, et al. · Cancer Research
Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer
2022 · Jonathan T Lei, Chen Huang, et al. · Cancer Research
Works count: 16
Citation count: 20
H-index: 3
I10-index: 1
Year
Topic
Type